These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11716139)

  • 21. [Clinical characteristics of painful dystonic foot response in patients with Parkinson's disease].
    Hara H; Wakayama Y; Kawase J
    Rinsho Shinkeigaku; 1989 Sep; 29(9):1101-5. PubMed ID: 2598534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine receptors and L-dopa-induced dyskinesia.
    Berthet A; Bezard E
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S8-12. PubMed ID: 20123563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
    Jones N; Bleickardt C; Mullins D; Parker E; Hodgson R
    Brain Res Bull; 2013 Sep; 98():163-9. PubMed ID: 23838432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.
    Carta M; Carlsson T; Muñoz A; Kirik D; Björklund A
    Prog Brain Res; 2008; 172():465-78. PubMed ID: 18772046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias.
    Stahl SM; Davis KL; Berger PA
    J Clin Psychopharmacol; 1982 Oct; 2(5):321-8. PubMed ID: 6127351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic high dose L-dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study.
    Zeng BY; Pearce RK; MacKenzie GM; Jenner P
    J Neural Transm (Vienna); 2001; 108(8-9):925-41. PubMed ID: 11716146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. L-dopa induced dyskinesias in asymmetrical parkinsonism.
    Murphy MJ
    Acta Neurol Latinoam; 1979; 25(1-2):47-52. PubMed ID: 583384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between tardive dyskinesia, L-Dopa-induced hyperkinesia and parkinsonism.
    Gerlach J
    Psychopharmacology (Berl); 1977 Mar; 51(3):259-63. PubMed ID: 403541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dyskinesias and the subthalamic nucleus.
    Benabid AL; Benazzouz A; Limousin P; Koudsie A; Krack P; Piallat B; Pollak P
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S189-92. PubMed ID: 10762147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
    Berg D; Godau J; Trenkwalder C; Eggert K; Csoti I; Storch A; Huber H; Morelli-Canelo M; Stamelou M; Ries V; Wolz M; Schneider C; Di Paolo T; Gasparini F; Hariry S; Vandemeulebroecke M; Abi-Saab W; Cooke K; Johns D; Gomez-Mancilla B
    Mov Disord; 2011 Jun; 26(7):1243-50. PubMed ID: 21484867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
    Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Foot dystonia heralding levodopa-induced dyskinesias in Parkinson disease.
    Pouclet H; Derkinderen P; Lebouvier T
    Clin Neurol Neurosurg; 2013 Feb; 115(2):235-6. PubMed ID: 22743235
    [No Abstract]   [Full Text] [Related]  

  • 34. Levodopa-induced dyskinesia in Parkinson's disease.
    Brotchie JM; Lee J; Venderova K
    J Neural Transm (Vienna); 2005 Mar; 112(3):359-91. PubMed ID: 15614429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
    Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA
    Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pathophysiology and therapy of L-Dopa-induced dyskinesia].
    Hadj Tahar A; Bézard E; Grondin R; Gross CE; Bédard PJ
    Rev Neurol (Paris); 2003 Dec; 159(12):1125-42. PubMed ID: 14978413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The spectrum of levodopa-induced dyskinesias.
    Fahn S
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S2-9; discussion S9-11. PubMed ID: 10762127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenesis of dyskinesias in Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Fabbrini G; Juncos JL; Chase TN
    Ann Neurol; 1989 May; 25(5):523-6. PubMed ID: 2774496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tardive and idiopathic oromandibular dystonia: a clinical comparison.
    Tan EK; Jankovic J
    J Neurol Neurosurg Psychiatry; 2000 Feb; 68(2):186-90. PubMed ID: 10644785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.